STAT+: Pharmalittle: A ‘King Kong’ of weight-loss drugs is looming; FTC orders Illumina to divest Grail
People who are overweight are flocking to Ozempic to slim down, but looming is Lilly's even more powerful weight-loss treatment, called Mounjaro.
Hello, everyone, and how are you today? We are doing just fine, thank you, since a cool breeze and sunny skies are enveloping the Pharmalot campus. Moreover, the official mascot is happily occupied since his favorite playmate is here for a week-long slumber party. Squirrels beware. This leaves us to focus on matters at hand, which start with brewing cups of stimulation — butter pecan, for those keeping track — and foraging for items of interest. Speaking of which, here is a new batch. Hope your day goes well, and do keep us in mind when something saucy occurs. …
People who are overweight are flocking to a drug called Ozempic to slim down, but looming is an even more powerful weight-loss treatment called Mounjaro, The Wall Street Journal says. The Eli Lilly diabetes drug helped a typical person with obesity who weighed 230 pounds lose up to 50 pounds during a test period of nearly 17 months. No anti-obesity drug has ever safely made such a difference. In the coming months, it is widely expected to get the go-ahead from U.S. health regulators to be prescribed for losing weight and keeping it off, Mounjaro could be one of the highest-selling drugs of all time with annual sales exceeding $25 billion. One diabetes doctor called it a “King Kong” of diet drugs.
What's Your Reaction?
